FR24C1022I1 - MODULATION OF COMPLEMENT ACTIVITY - Google Patents

MODULATION OF COMPLEMENT ACTIVITY

Info

Publication number
FR24C1022I1
FR24C1022I1 FR24C1022C FR24C1022C FR24C1022I1 FR 24C1022 I1 FR24C1022 I1 FR 24C1022I1 FR 24C1022 C FR24C1022 C FR 24C1022C FR 24C1022 C FR24C1022 C FR 24C1022C FR 24C1022 I1 FR24C1022 I1 FR 24C1022I1
Authority
FR
France
Prior art keywords
modulation
complement activity
complement
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1022C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RA Pharmaceuticals Inc
Original Assignee
RA Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54834568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR24C1022(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by RA Pharmaceuticals Inc filed Critical RA Pharmaceuticals Inc
Publication of FR24C1022I1 publication Critical patent/FR24C1022I1/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR24C1022C 2014-06-12 2024-05-16 MODULATION OF COMPLEMENT ACTIVITY Active FR24C1022I1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462011368P 2014-06-12 2014-06-12
US201462077460P 2014-11-10 2014-11-10
US201562108772P 2015-01-28 2015-01-28
PCT/US2015/035473 WO2015191951A2 (en) 2014-06-12 2015-06-12 Modulation of complement activity

Publications (1)

Publication Number Publication Date
FR24C1022I1 true FR24C1022I1 (en) 2024-07-19

Family

ID=54834568

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1022C Active FR24C1022I1 (en) 2014-06-12 2024-05-16 MODULATION OF COMPLEMENT ACTIVITY

Country Status (29)

Country Link
US (7) US10106579B2 (en)
EP (4) EP3154561B1 (en)
JP (4) JP6432954B2 (en)
KR (3) KR101981532B1 (en)
CN (1) CN106456701B (en)
AP (1) AP2016009612A0 (en)
AU (3) AU2015274482B2 (en)
BR (3) BR122023024819A2 (en)
CA (3) CA3241273A1 (en)
CY (2) CY1122227T1 (en)
DK (2) DK3154561T3 (en)
ES (2) ES2750556T3 (en)
FI (1) FIC20240015I1 (en)
FR (1) FR24C1022I1 (en)
HR (2) HRP20211561T8 (en)
HU (3) HUE055931T2 (en)
IL (3) IL249093B (en)
LT (2) LT3154561T (en)
MX (2) MX2016016449A (en)
NL (1) NL301275I2 (en)
NZ (3) NZ727420A (en)
PL (2) PL3628680T3 (en)
PT (2) PT3154561T (en)
RS (2) RS59353B1 (en)
RU (1) RU2670988C2 (en)
SG (1) SG11201610222UA (en)
SI (2) SI3628680T1 (en)
WO (1) WO2015191951A2 (en)
ZA (3) ZA201706379B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3628680T3 (en) 2014-06-12 2022-01-10 Ra Pharmaceuticals, Inc. Modulation of complement activity
HRP20211824T1 (en) 2015-01-28 2022-03-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
HRP20230182T1 (en) 2015-12-16 2023-04-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
US11026945B2 (en) 2016-04-29 2021-06-08 The Trustees Of The University Of Pennsylvania Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation
CA3045114A1 (en) * 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2019246387A1 (en) * 2018-06-21 2019-12-26 Ra Pharmaceuticals, Inc. Cyclic peptides for pcsk9 inhibition
US11530244B2 (en) 2018-06-21 2022-12-20 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
EP3810176A4 (en) 2018-06-21 2022-05-18 RA Pharmaceuticals, Inc. Cyclic polypeptides for pcsk9 inhibition
MA53986A (en) 2018-10-22 2022-01-26 Ra Pharmaceuticals Inc TREATMENT OF NEUROLOGICAL DISEASES WITH ZILUCOPLAN
WO2020185541A2 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
TW202106290A (en) 2019-04-24 2021-02-16 美商Ｒａ製藥公司 Compositions and methods for modulating complement activity
ES2973767T3 (en) 2019-06-04 2024-06-24 Ra Pharmaceuticals Inc Treatment of inflammatory diseases with complement inhibitors
CN114423445A (en) 2019-09-12 2022-04-29 Ra制药公司 Treatment of neurological diseases using complement inhibitors
US11932705B2 (en) 2020-12-18 2024-03-19 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
WO2022177635A2 (en) * 2021-02-22 2022-08-25 Ra Pharmaceuticals, Inc. Compositions and methods for microbial disease treatment
WO2023215294A1 (en) * 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Complement pathway inhibition for wound healing
WO2024039636A1 (en) * 2022-08-16 2024-02-22 Ps Therapy, Inc. Methods of use for disulfiram and metabolites thereof

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361943B1 (en) 1996-10-17 2002-03-26 Mitsubishi Chemical Corporation Molecule that homologizes genotype and phenotype and utilization thereof
US4271068A (en) 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033940A (en) 1975-11-12 1977-07-05 Armour Pharmaceutical Company Cyclization of peptides
US4216141A (en) 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5371109A (en) 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
DE69032483T2 (en) 1989-10-05 1998-11-26 Optein, Inc., Seattle, Wash. CELL-FREE SYNTHESIS AND ISOLATION OF GENES AND POLYPEPTIDES
US5585353A (en) 1990-02-02 1996-12-17 The Rockefeller University Antibiotic peptides containing D-amino acids
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
AU684510B2 (en) 1993-05-28 1997-12-18 Chiron Corporation Method for selection of biologically active peptide sequences
EP0710243B1 (en) 1993-06-29 2000-06-14 Ferring B.V. Synthesis of cyclic peptides
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5834318A (en) 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
JP3692542B2 (en) 1997-01-21 2005-09-07 ザ ジェネラル ホスピタル コーポレーション Protein selection using RNA-protein fusions
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
EP0896001A1 (en) 1997-08-08 1999-02-10 Daicel Chemical Industries, Ltd. Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
EP1102742B1 (en) 1998-08-07 2006-06-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2000021559A2 (en) 1998-10-09 2000-04-20 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US6962781B1 (en) 2000-05-19 2005-11-08 Proteonova, Inc. In vitro evolution of nucleic acids and encoded polypeptide
US7244701B2 (en) 2000-06-16 2007-07-17 Zealand Phama A/S Diuretic peptide conjugate
WO2004035624A2 (en) * 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
EP1628530B8 (en) 2003-05-15 2012-08-01 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
CA2579635A1 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
CA2537029C (en) 2003-11-26 2013-03-12 Likan Liang Micellar systems useful for delivery of lipophilic or hydrophobic compounds
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20060027059A1 (en) 2004-08-09 2006-02-09 Chih-Ching Hsien Extendable handle device
US20090054623A1 (en) * 2004-12-17 2009-02-26 Neose Technologies, Inc. Lipo-Conjugation of Peptides
PL1844337T3 (en) 2005-01-24 2013-12-31 Pepscan Systems Bv Binding compounds, immunogenic compounds and peptidomimetics
CA2610502A1 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
BRPI0618160A2 (en) 2005-05-26 2011-08-16 Univ Colorado Alternative complement pathway inhibition for treatment of traumatic brain damage, spinal cord damage and related conditions
CA2609810C (en) 2005-06-06 2012-05-22 Camurus Ab Glp-1 analogue formulations
CA2624393C (en) 2005-11-04 2016-01-05 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
AU2007225044C1 (en) 2006-03-15 2018-03-29 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP1876183A1 (en) * 2006-07-04 2008-01-09 Technische Universität München Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins
CA3154415A1 (en) 2006-10-10 2008-04-17 Regenesance B.V. Anti-sense oligonucleotide for use in facilitating axonal regeneration
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
WO2008109742A1 (en) 2007-03-06 2008-09-12 Novo Nordisk A/S Modulation of complement system activation for treatment of bleeding-related inflammation
EP2129681A2 (en) * 2007-03-22 2009-12-09 Novartis Ag C5 antigens and uses thereof
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
CN101674824A (en) 2007-04-30 2010-03-17 爱尔康研究有限公司 Treatment of age-related macular degeneration using inhibitors of complement factor d
CA2690124A1 (en) 2007-06-07 2008-12-18 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement-associated disorders
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
EP2207530A4 (en) 2007-10-02 2013-09-11 Potentia Pharmaceuticals Inc Sustained delivery of compstatin analogs from gels
WO2009067191A2 (en) 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
WO2009121065A2 (en) 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
US20100093624A1 (en) 2008-07-30 2010-04-15 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
AR072897A1 (en) * 2008-08-05 2010-09-29 Novartis Ag COMPOSITIONS AND METHODS FOR ANTIBODIES GOING TO COMPLEMENT PROTEIN C5
EP2331561A4 (en) 2008-09-03 2013-02-27 Xenome Ltd Libraries of peptide conjugates and methods for making them
CN109045296A (en) 2008-11-10 2018-12-21 阿雷克森制药公司 For treating the method and composition of complement associated disorders
AU2009230735B1 (en) 2009-01-08 2010-01-21 Shane Ramodien Electronic equipment housing
KR101788040B1 (en) 2009-10-16 2017-10-19 오메로스 코포레이션 Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
US10239937B2 (en) 2009-11-05 2019-03-26 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
CN102791731B (en) 2009-12-16 2016-04-20 诺沃—诺迪斯克有限公司 GLP-1 sum analogous to general Dedekind sum
US9172511B2 (en) 2009-12-24 2015-10-27 Samsung Electronics Co., Ltd. Apparatus and method of communicating automatic repeat request (ARQ) feedback in a wireless communication network
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
ES2659409T3 (en) 2010-03-12 2018-03-15 The Regents Of The University Of California Lipid-peptide-polymer conjugates and nanoparticles thereof
WO2011139343A2 (en) * 2010-04-28 2011-11-10 Wu Nian Amino acid linked peg-lipid conjugates
EP2563359A1 (en) 2010-04-30 2013-03-06 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
KR20210021101A (en) 2011-04-08 2021-02-24 유니버시티 오브 레스터 Methods for treating conditions associated with masp-2 dependent complement activation
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
CN102321170B (en) * 2011-09-14 2013-11-13 深圳翰宇药业股份有限公司 Liraglutide variant and conjugate thereof
US20140296147A1 (en) * 2011-10-06 2014-10-02 The Medicines Company Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
PL2817329T3 (en) * 2012-02-20 2019-07-31 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
ES2755104T3 (en) 2012-05-17 2020-04-21 Ra Pharmaceuticals Inc Peptide and peptidomimetic inhibitors
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2014004733A1 (en) 2012-06-26 2014-01-03 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
US20150330989A1 (en) 2012-11-15 2015-11-19 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US9700633B2 (en) * 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
WO2015025312A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
SG11201607740TA (en) 2014-03-20 2016-10-28 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia
PL3628680T3 (en) * 2014-06-12 2022-01-10 Ra Pharmaceuticals, Inc. Modulation of complement activity
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
WO2016118652A1 (en) 2015-01-21 2016-07-28 Pacira Pharmaceuticals, Inc. Multivesicular liposome formulations of tranexamic acid
HRP20211824T1 (en) * 2015-01-28 2022-03-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
HRP20230182T1 (en) 2015-12-16 2023-04-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
CA3045114A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
WO2019051436A1 (en) 2017-09-11 2019-03-14 Ra Pharmaceuticals, Inc. Formulations for compound delivery
RU2020117578A (en) 2017-12-04 2022-01-14 Ра Фармасьютикалз, Инк. COMPLEMENT ACTIVITY MODULATORS
WO2020185541A2 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
TW202106290A (en) 2019-04-24 2021-02-16 美商Ｒａ製藥公司 Compositions and methods for modulating complement activity

Also Published As

Publication number Publication date
KR101981532B1 (en) 2019-09-02
JP2022034057A (en) 2022-03-02
LT3628680T (en) 2021-11-25
WO2015191951A2 (en) 2015-12-17
NZ727420A (en) 2018-06-29
BR122023024819A2 (en) 2023-12-26
RU2670988C2 (en) 2018-10-29
JP7454545B2 (en) 2024-03-22
JP2019048834A (en) 2019-03-28
AU2015274482A1 (en) 2017-01-12
DK3628680T3 (en) 2021-10-11
ZA201900497B (en) 2019-10-30
CN111187338A (en) 2020-05-22
KR102503319B1 (en) 2023-02-28
JP7002597B2 (en) 2022-02-04
EP3628680B1 (en) 2021-09-08
HRP20211561T1 (en) 2021-12-24
SG11201610222UA (en) 2017-01-27
EP3154561A2 (en) 2017-04-19
KR20190057420A (en) 2019-05-28
CA3241273A1 (en) 2015-12-17
IL273746B (en) 2021-03-25
NZ736573A (en) 2024-03-22
CN106456701B (en) 2020-01-07
CN106456701A (en) 2017-02-22
BR112016029076A2 (en) 2018-06-05
US20200123202A1 (en) 2020-04-23
US20190119328A1 (en) 2019-04-25
NL301275I2 (en) 2024-06-20
US20170137468A1 (en) 2017-05-18
EP3154561B1 (en) 2019-09-04
SI3154561T1 (en) 2019-11-29
IL249093A0 (en) 2017-01-31
HRP20211561T8 (en) 2022-03-04
CA2949985A1 (en) 2015-12-17
ZA201706379B (en) 2018-12-19
KR20170003993A (en) 2017-01-10
RU2016147080A (en) 2018-06-01
RS59353B1 (en) 2019-10-31
FIC20240015I1 (en) 2024-05-28
PT3154561T (en) 2019-10-25
AU2021204313A1 (en) 2021-07-22
IL281264A (en) 2021-04-29
RU2018136750A (en) 2018-11-06
AP2016009612A0 (en) 2016-12-31
HUE045646T2 (en) 2020-01-28
HUE055931T2 (en) 2022-01-28
ES2750556T3 (en) 2020-03-26
EP3628680A1 (en) 2020-04-01
AU2015274482B2 (en) 2018-11-08
US11014965B2 (en) 2021-05-25
AU2021204313B2 (en) 2024-01-04
CA2949985C (en) 2023-10-17
HRP20191763T1 (en) 2019-12-27
SI3628680T1 (en) 2021-12-31
US10562934B2 (en) 2020-02-18
ES2895029T3 (en) 2022-02-17
BR122021025449B1 (en) 2024-02-15
JP2017523232A (en) 2017-08-17
DK3154561T3 (en) 2019-10-07
EP4223317A2 (en) 2023-08-09
MX2021009309A (en) 2021-10-26
US20210246167A1 (en) 2021-08-12
US10435438B2 (en) 2019-10-08
US20200002380A1 (en) 2020-01-02
US20180371019A1 (en) 2018-12-27
IL281264B (en) 2022-05-01
BR112016029076A8 (en) 2022-02-08
JP6432954B2 (en) 2018-12-05
PL3154561T3 (en) 2019-12-31
RU2016147080A3 (en) 2018-06-01
LT3154561T (en) 2019-11-25
ZA202001859B (en) 2021-04-28
CY1124595T1 (en) 2022-07-22
EP4223317A3 (en) 2023-09-27
IL249093B (en) 2020-05-31
AU2019200828B2 (en) 2021-04-08
US10106579B2 (en) 2018-10-23
BR112016029076B1 (en) 2024-02-15
PL3628680T3 (en) 2022-01-10
RU2018136750A3 (en) 2021-10-19
AU2019200828A1 (en) 2019-02-28
MX2016016449A (en) 2017-08-24
US11535650B1 (en) 2022-12-27
KR102346228B1 (en) 2022-01-04
KR20220002727A (en) 2022-01-06
WO2015191951A3 (en) 2016-03-03
IL273746A (en) 2020-05-31
HUS2400015I1 (en) 2024-06-28
PT3628680T (en) 2021-10-07
US10208089B2 (en) 2019-02-19
EP3154561A4 (en) 2018-04-18
RS62428B1 (en) 2021-11-30
EP3973994A1 (en) 2022-03-30
JP2020128417A (en) 2020-08-27
NZ761610A (en) 2024-03-22
CA3174909A1 (en) 2015-12-17
JP6770043B2 (en) 2020-10-14
CY1122227T1 (en) 2020-11-25
US11965040B2 (en) 2024-04-23

Similar Documents

Publication Publication Date Title
FR24C1022I1 (en) MODULATION OF COMPLEMENT ACTIVITY
DK3347030T3 (en) USE OF PASTEURIZED AKKERMANSIA FOR THE TREATMENT OF METABLE DISEASES
DK3107563T3 (en) GLYCOM TARGETED THERAPEUTIC AGENTS
DK3240612T3 (en) PROCEDURES FOR THE TREATMENT OF RHINTH DISEASES
DK3231444T3 (en) New treatment
DK3157534T3 (en) ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS
DK3113761T3 (en) Microcapsules containing active agent
DK3132009T3 (en) COURSE OF ACTION
DK3160252T3 (en) NEW Grease-free confectionery
DK3143123T3 (en) MICRORNA-INDUCTION OF CARDIOLOGICAL REGENERATION
BR112016026078A2 (en) ABSORBENT PRODUCT
DE112015002229A5 (en) Formulations for the treatment of hyperthyroidism
FR3024647B1 (en) TRANSAT OF PUERICULTURE
TH1601001543A (en) A combination of active ingredients
TH1401001808B (en) skin scrubber
TH1401001806B (en) skin scrubber
TH1601002047A (en) Elements for regulating the expression of C9ORF72
ES1124182Y (en) I LOVE
TH1501006567A (en) skin cleansing ingredients
FR3022783B1 (en) ARTIFICIAL SEBUM
TH1501006414B (en) absorbent product
TH1501003886A (en) Cleanser
TH1501003893A (en) skin care elements
ES1109130Y (en) Disposable tie
TH1501006261B (en) absorbent product